Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.

Miller, David M; Faulkner-Jones, Beverly E; Stone, James R; Drews, Reed E

Miller, David M; Faulkner-Jones, Beverly E; Stone, James R; Drews, Reed E.

Afiliação

Miller DM; Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Faulkner-Jones BE; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
Stone JR; Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Drews RE; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

JAAD Case Rep ; 3(5): 412-415, 2017 Sep.

Article em En | MEDLINE | ID: mdl-28932782

Palavras-chave

DICB, dual immune checkpoint blockade; ICB, immune checkpoint blockade; cSCC, cutaneous squamous cell carcinoma; immune checkpoint blockade; ipi/nivo, ipilimumab and nivolumab; ipilimumab; mcSCC, metastatic cSCC; nivolumab; squamous cell carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article